GlassScriptPhysician profile
Jennifer Y Ding
NPI 1457779027
$2,988.70
in general payments reported to CMS, 2019-2025
43 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $206 · 2023: $471 · 2024: $703 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,570.42 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $399.95 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $235.40 | 2021-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $218.84 | 2023-2025 | Enhertu, Imfinzi, Tagrisso |
| Daiichi Sankyo INC. | $206.94 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Pharmaessentia USA Corporation | $156.82 | 2023-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $148.04 | 2023 | Clonoseq |
| Amgen INC. | $124.70 | 2022 | |
| Pfizer INC. | $108.33 | 2024-2025 | |
| Janssen Biotech, INC. | $104.31 | 2024-2025 | Tecvayli, Rybrevant |
| Celgene Corporation | $100.20 | 2024-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $84.76 | 2024-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $76.47 | 2024-2025 | Ojjaara, Blenrep |
| Genmab U.S., INC. | $73.81 | 2024-2025 | Epkinly |
| Astellas Pharma US INC | $63.50 | 2024-2025 | Vyloy |
| Taiho Oncology, INC. | $60.27 | 2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.